Saturday 17 October 2026 Export MBOT’s income statement to Excel — free account

Microbot Medical Inc.

MBOT Healthcare Medical Instruments & Supplies

In the quarter to June 2026, revenue grew 1,047.6%, EPS grew 20.0% and free cash flow fell 98.7%, each against the same quarter a year earlier.

0.95 0.00 0.00%

Follow MBOT

Alert me

Market cap: $63.8M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: −19.40
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 9.13%

Capital & Financial Ratios $m

Market Cap 63.80

Revenue 0.41

Net Income (16.34)

Free Cash Flow (17.93)

Net Debt (67.57)

Current Ratio 18.56

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 154.46

P/B ratio 0.93

Past 5Y EPS Growth —

This Y EPS Growth (3.45%)

Next Y EPS Growth (1.11%)

Next Y revenue growth —

Next 5Y EPS Growth 18.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 89.42%

10-year low 10-year high

P/B against its own 10 years 1.67%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6	6	79	68
Receivables	1	—	—	0
Inventory	—	—	1	3
Other	—	—	—	1
	8	6	80	72

	2023	2024	2025	Q'26
Payables	0	0	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	4	2	3	4

Compound Annual Growth %

	10y	5y	3y
Sales	—	0.39%	(6.05%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	26.12%	119.94%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(3)	(3)	(4)	(4)	(13)
’24	(2)	(2)	(3)	(2)	(9)
’23	(3)	(2)	(2)	(2)	(9)
’22	(3)	(3)	(3)	(2)	(12)
’21	(2)	(2)	(2)	(3)	(9)
’20	(2)	(1)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(3)	(3)	(4)	(4)	(13)
’24	(2)	(2)	(3)	(2)	(9)
’23	(3)	(2)	(2)	(2)	(9)
’22	(3)	(3)	(3)	(2)	(12)
’21	(2)	(2)	(2)	(3)	(9)
’20	(2)	(1)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	(0.08)	—	—	—
’25	(0.08)	(0.10)	(0.07)	(0.04)	(0.29)
’24	(0.17)	(0.17)	(0.20)	(0.20)	(0.73)
’23	(0.36)	(0.25)	(0.21)	(0.26)	(1.05)
’22	(0.45)	(0.49)	(0.49)	(0.38)	(1.81)
’21	(0.34)	(0.35)	(0.36)	(0.54)	(1.59)
’20	(0.31)	(0.26)	(0.35)	(0.37)	(1.29)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	44.55	15.00	1.38	1.62	4.30	4.31	3.00	1.00	0.82	1.11	Analyst estimates 2026–2028 Powerpack
	High	729.00	149.10	17.25	20.15	15.75	10.69	7.91	4.37	2.35	4.67
People
People	Employees	7	7	9	9	2	3	21	22	21	43
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(10)	(8)	(7)	(7)	(9)	(11)	(13)	(11)	(11)	(13)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(10)	(8)	(7)	(7)	(9)	(11)	(13)	(11)	(11)	(13)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(10.14)	(3.52)	(2.41)	(1.70)	(1.29)	(1.59)	(1.81)	(1.05)	(0.73)	(0.29)
	Cash flow	(0.82)	(2.23)	(1.83)	(1.51)	(1.02)	(1.32)	(1.59)	(0.84)	(0.56)	(0.28)
	Capex	(0.03)	(0.03)	(0.08)	0.01	(0.01)	(0.01)	(0.01)	0.00	0.00	0.00
	Free cash flow	(0.85)	(2.26)	(1.91)	(1.50)	(1.03)	(1.33)	(1.60)	(0.84)	(0.57)	(0.29)
	Book value	2.30	4.80	0.46	7.39	3.42	2.02	1.00	0.44	0.23	1.69
	Shares, m	1	2	3	4	7	7	7	10	16	46
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(1)	(5)	(5)	(6)	(7)	(9)	(12)	(9)	(9)	(13)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(1)	(5)	(6)	(6)	(7)	(9)	(12)	(9)	(9)	(13)
Balance, $m
Balance, $m	Working capital	3	10	1	31	24	14	7	4	3	76
	Total debt	0	—	—	1	1	0	0	—	—	—
	Net debt	(3)	(11)	(5)	(36)	(25)	(16)	(8)	(6)	(6)	(79)
	Shareholders’ equity	2	10	1	32	24	14	7	5	4	78
Returns, %
Returns, %	ROA	(292.99)	(83.50)	(84.86)	(33.54)	(28.92)	(52.56)	(100.12)	(120.24)	(159.40)	(30.01)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(558.34)	(94.90)	(123.11)	(44.09)	(32.84)	(58.48)	(121.53)	(182.19)	(284.97)	(32.42)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2014 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NYXH Nyxoah SA	$121.2M	— (loss-making)	— (loss-making)	+486.62% (above 0%: growing)	n/m	+4.01% (above 0%: growing)	59.73%	(268.25%)	Compare
STXS Stereotaxis Inc.	$105.2M	— (loss-making)	— (loss-making)	−12.82% (below 0%: shrinking)	n/m	+0.45% (above 0%: growing)	58.49%	(59.56%)	Compare
MBOT Microbot Medical Inc.	$63.8M	— (loss-making)	—	+1,047.62% (above 0%: growing)	n/m	−98.72% (below 0%: shrinking)	(266.80%)	(2,567.63%)
ZTEKF Zentek Ltd.	$62.3M	— (loss-making)	—	−95.36% (below 0%: shrinking)	n/m	−254.61% (below 0%: shrinking)	0.00%	0.00%	Compare
DXR Daxor Corporation	$59.6M	4.7×	7.6×	−27.62% (below 0%: shrinking)	n/m	−88.56% (below 0%: shrinking)	0.00%	0.00%	Compare
POCI Precision Optics Corp.	$47.7M	— (loss-making)	—	+41.95% (above 0%: growing)	n/m	−45.64% (below 0%: shrinking)	25.34%	(1.21%)	Compare
NEPH Nephros Inc.	$38.1M	23.4×	76.0×	+36.16% (above 0%: growing)	+450.00% (above 0%: growing)	−31.49% (below 0%: shrinking)	66.91%	20.16%	Compare
HBIO Harvard Bioscience, Inc.	$37.8M	— (loss-making)	— (loss-making)	+11.13% (above 0%: growing)	n/m	−123.43% (below 0%: shrinking)	55.57%	(4.30%)	Compare
MLSS Milestone Scientific, Inc.	$29.6M	— (loss-making)	— (loss-making)	+22.27% (above 0%: growing)	n/m	+66.68% (above 0%: growing)	67.24%	(37.37%)	Compare
Median of peers	$53.7M	—	—	+16.70%	—	−38.56%	57.03%	(2.75%)

All 55 Medical Instruments & Supplies stocks →

Microbot Medical Inc. (MBOT) key facts

Microbot Medical Inc. (MBOT) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MBOT traded at $0.95, a market capitalization of $63.8 million.
Return on equity was −32.4% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.